论文部分内容阅读
报告了以伊达比星（ＩＤＡ）为主联合阿糖胞替（Ａｍ－Ｃ）、长春新碱（ＶＣＲ）、强的松等药物治疗８例难治性复发性急性白血病，其中ＡＭＬ５例，ＡＬＬ３例。除１例ＡＭＬ于治疗中脑出血死亡外，其余７例中，３例完全缓解（４２．８％），２例部分缓解（２８．７％），２例无效，总有效率７１．５％。８例均有明显血像抑制，４例骨髓增生严重减低，２例并发严重肺部感染，１例并发面部急性蜂窝织炎，但无１例出现严重心、肝、肾并发症。初步结果表明，伊达比星是治疗难治性复发性急性白血病更有效的药物之一，但血像和骨髓像抑制明显，应加强支持保护治疗。
Eight patients with refractory recurrent acute leukemia were treated with idarubicin (Am-C), vincristine (VCR), prednisone and the like, with 5 cases of AML, ALL3 cases. Except one case of AML died of intracerebral hemorrhage, three of the seven cases were completely relieved (42.8%), two partially relieved (28.7%), two were ineffective and the total effective rate was 71.5% . 8 cases had obvious blood image suppression, 4 cases of severe myelodysplasia, 2 cases of severe pulmonary infection, 1 case of acute facial cellulitis, but none of the patients had serious heart, liver and kidney complications. Preliminary results show that, Ida Bixing is a more effective treatment of refractory recurrent acute leukemia drugs, but blood and bone marrow imaging significantly inhibited, should be strengthened to support the protection of treatment.